Blocking CDK7 as a new approach for aggressive ovarian cancer
Targeting CDK7 in high-grade serous ovarian carcinoma
This work explores whether blocking a protein called CDK7 can help treat women with high-grade serous ovarian cancer, especially tumors with CDK7 loss or BRCA-related DNA repair problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11131193 on NIH RePORTER |
What this research studies
Researchers are testing drugs that block CDK7, a protein some ovarian tumors rely on, using tumor samples and laboratory models to see which cancers are most vulnerable. They are focusing on high-grade serous ovarian cancer and tumors that have lost one copy of CDK7 or have BRCA1/2-related defects. The team will also look at whether CDK7 blockade makes tumors more sensitive to existing DNA-damaging treatments like PARP inhibitors or platinum chemotherapy. The goal is to identify tumor features that predict benefit and to guide future treatment options for patients.
Who could benefit from this research
Good fit: Women with advanced high-grade serous ovarian carcinoma, particularly those whose tumors show CDK7 hemizygous loss or BRCA1/2 mutations, would be the best match.
Not a fit: Patients with other ovarian cancer subtypes or tumors that lack CDK7 changes are less likely to benefit from CDK7-targeted approaches.
Why it matters
Potential benefit: If successful, blocking CDK7 could slow tumor growth and make ovarian cancers more responsive to existing therapies such as PARP inhibitors and platinum drugs.
How similar studies have performed: Laboratory studies have shown CDK7 inhibitors can kill cancer cells and boost sensitivity to DNA-damaging drugs, but clinical use in patients remains experimental.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Zhang, Lin — University of Pennsylvania
- Study coordinator: Zhang, Lin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.